Munich, Germany, November 16, 2016; ISBN: 978-94-91526-09-1. Also published by the following supporting organizations: www.ephor.eu, www.vlaamse-ouderenraad.be, www.bop.brussels
Determination and validation of relevant issues in cost-effectiveness evaluation. Guidance on the integration of these issues into the cost-effectiveness model.
Munich, Germany, March 14, 2014, ISBN: 978-94-91526-05-3.
Role of cost-effectiveness evaluation and other economic instruments in current coverage decisions. Guidance on coverage decision-making in orphan disease: an algorithmic approach.
Munich, Germany, February 28, 2014, ISBN: 978-94-91526-04-6.
Bodegraven, the Netherlands, March 26, 2019; ISBN 978-94-91526-13-8.
Download report
Published articles
Health Care Publications
"Dual pathway inhibition has added value in patients with stable cardiovascular disease".
Dutch article: "Combinatietherapie heeft een toegevoegde waarde bij vaatziekte". Hugo ten Cate, Bernard Elsman, Wiek van Gilst, Lisa de Jong, Hans van Laarhoven, Anho Liem en Michiel Warlé. Pharm Weekbl Aug 16, 2019: 154-33/34.
"Cost-effectiveness in Clostridium difficile treatment decision-making".
English article Mark JC Nuijten, Josbert J Keller, Caroline E Visster, Ken Redekop, Eric Claassen, Peter Speelman, Marja H Pronk. World J Clin Cases 2015 November 16:3(11):935-941.
"Patient-perspective in the reimbursement assessment of direct anticoagulant products for atrial fibrillation and venous thromboembolism".
Dutch article: "Patiëntenperspectief in de beoordeling van direct werkende orale anticoagulantia bij atriumfibrilleren en veneuze trombo-embolie". Koos Brouwers, Jeroen Hendriks, Hans van Laarhoven, Gerlof Jukema, Marja Pronk. Pharm Weekbl 2015:9(4):72-2.